Oragenics, Inc. (NYSEAMERICAN:OGEN) Short Interest Up 806.3% in January

Oragenics, Inc. (NYSEAMERICAN:OGEN) was the target of a large increase in short interest in January. As of January 30th, there was short interest totaling 524,157 shares, an increase of 806.3% from the January 15th total of 57,838 shares. Based on an average daily trading volume, of 1,798,797 shares, the short-interest ratio is currently 0.3 days. Approximately 13.7% of the company’s stock are sold short. Approximately 13.7% of the company’s stock are sold short. Based on an average daily trading volume, of 1,798,797 shares, the short-interest ratio is currently 0.3 days.

Institutional Investors Weigh In On Oragenics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Clear Street LLC purchased a new stake in Oragenics in the 2nd quarter worth about $270,000. Sabby Management LLC bought a new stake in Oragenics during the third quarter valued at about $77,000. Finally, Bank of America Corp DE increased its position in Oragenics by 7,374.0% in the 2nd quarter. Bank of America Corp DE now owns 15,546 shares of the company’s stock worth $59,000 after buying an additional 15,338 shares during the period. 18.71% of the stock is currently owned by institutional investors.

Oragenics Stock Up 3.4%

Oragenics stock traded up $0.02 during mid-day trading on Tuesday, reaching $0.72. 73,098 shares of the company were exchanged, compared to its average volume of 933,608. The firm’s 50-day simple moving average is $0.85 and its two-hundred day simple moving average is $1.07. Oragenics has a twelve month low of $0.63 and a twelve month high of $9.60.

Oragenics (NYSEAMERICAN:OGEN) last released its quarterly earnings results on Friday, November 7th. The company reported ($1.96) earnings per share for the quarter.

Oragenics Company Profile

Oragenics, Inc is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.

The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures.